Trial Profile

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SX 682 (Primary) ; Tislelizumab (Primary)
Indications Adenocarcinoma; Pancreatic cancer
Focus Therapeutic Use

Most Recent Events

13 Oct 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Sep 2023 to 1 Nov 2023.
13 Oct 2023 Planned initiation date changed from 1 Sep 2023 to 1 Nov 2023.
16 Aug 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com